Evaluation of Plasma pTau217 plus Abeta42/40, and pTau217/Abeta42 Ratio as Confirmatory Tests for Amyloid Pathology in Alzheimer’s Disease (AD) (N4.003)
Multiple analytical approaches, based on plasma pTau217 and Aβ42/40 measurements, are evaluated using discriminatory performance for amyloid PET with the goal of developing a confirmatory test for Aβ pathology demonstrating ≥90% sensitivity and specificity.
Authors
- James D. Doecke (ORCID: https://orcid.org/0000-0003-2863-0293)
- Christopher C. Rowe (ORCID: https://orcid.org/0000-0003-3910-2453)
- John Winslow (ORCID: https://orcid.org/0000-0003-2701-2493)
- Ahmed Chenna (ORCID: https://orcid.org/0000-0001-6201-2494)
- Christos J. Petropoulos (ORCID: https://orcid.org/0000-0001-5496-8090)
- Colin L. Masters (ORCID: https://orcid.org/0000-0003-3072-7940)
- Stephanie R. Rainey‐Smith (ORCID: https://orcid.org/0000-0001-7328-9624)
- Youssouf Badal
- Ralph N. Martins (ORCID: https://orcid.org/0000-0002-4828-9363)
- Robert Martone (ORCID: https://orcid.org/0000-0001-7776-6109)
- Christopher Fowler (ORCID: https://orcid.org/0000-0003-1397-0359)
- Brandon Yee
- Simon M. Laws (ORCID: https://orcid.org/0000-0002-4355-7082)
- Mintzu Lo
Institutions
- Edith Cowan University (AU)
- Commonwealth Scientific and Industrial Research Organisation (AU)
- The University of Melbourne (AU)
- Murdoch University (AU)
- Florey Institute of Neuroscience and Mental Health (AU)
- LabCorp (United States) (US)
- Australian e-Health Research Centre (AU)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211434
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16